Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
0.889
+0.019 (2.18%)
Dec 29, 2023, 4:30 PM EST - Market closed
Achilles Therapeutics Stock Forecast
Stock Price Forecast
According to 2 stock analysts, the average 12-month stock price forecast for ACHL stock stock is $5.75, which predicts an increase of 546.79%. The lowest target is $0.50 and the highest is $11. On average, analysts rate ACHL stock stock as a buy.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACHL stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $1 | Strong Buy → Sell | Downgrades | $7 → $1 | -43.76% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +1,137.35% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +1,137.35% | May 11, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +1,812.26% | Dec 7, 2022 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +799.89% | Dec 7, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.83
from -1.82
EPS Next Year
-1.65
from -1.83
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | n/a | 84.0M |
| Avg | n/a | n/a | n/a | n/a | n/a | 81.6M |
| Low | n/a | n/a | n/a | n/a | n/a | 78.4M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | - |
| Avg | - | - | - | - | - | - |
| Low | - | - | - | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -1.88 | -0.93 | -3.08 |
| Avg | -1.83 | -1.65 | -2.99 |
| Low | -1.75 | -2.29 | -2.87 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.